Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GamaSTAN is a brand name for immune globulin (human), a sterile solution of concentrated antibodies (primarily IgG) derived from pooled human plasma. Developed and marketed by Grifols Therapeutics, it is administered via intramuscular injection to provide immediate, passive immunity. It is primarily indicated for post-exposure prophylaxis of hepatitis A and to prevent or modify the clinical course of measles, rubella, and varicella in susceptible individuals. The product contains 15–18% protein and is stabilized with glycine. Unlike intravenous immune globulin (IVIG) products, GamaSTAN is designed strictly for intramuscular use, with peak IgG levels typically reached approximately 2 days after administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on immune globulin (human).